Nolet Chris 4
4 · Revance Therapeutics, Inc. · Filed May 7, 2021
Insider Transaction Report
Form 4
Nolet Chris
Director
Transactions
- Award
Common Stock
2021-05-05+4,013→ 19,013 total - Award
Stock Option (Right to buy)
2021-05-05+7,551→ 7,551 totalExercise: $27.91Exp: 2031-05-04→ Common Stock (7,551 underlying)
Footnotes (2)
- [F1]Represents an annual restricted stock award (the "RSA") granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the one year anniversary, May 5, 2022, subject to Mr. Nolet's Continuous Service (as defined the Issuer's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
- [F2]The shares subject to the stock option shall vest on the one year anniversary, May 5, 2022, subject to Mr. Nolet's Continuous Service (as defined in the Plan) through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.